NATCO Pharma Limited has successfully completed the verification of all securities processed for dematerialization during the fourth quarter of the financial year. The company confirmed that all share certificates received have been formally mutilated and cancelled, with the records of both NSDL and CDSL updated accordingly to reflect the registered owners within the mandated 15-day timeframe.
Confirmation of Dematerialization Process
NATCO Pharma Limited has provided formal confirmation regarding the processing of securities for the quarter ended March 31, 2026. This process ensures that all share certificates received for dematerialization are properly validated, mutilated, and cancelled to prevent unauthorized circulation. This step is critical for maintaining accurate records within the national depositories.
Regulatory Compliance and Record Keeping
The company, in coordination with its registrar, Venture Capital and Corporate Investments Private Limited, has verified that all necessary updates were made to the National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) registries. By adhering to the 15-day turnaround period from the receipt of valid Dematerialization Request Forms (DRF), the company ensures a seamless experience for shareholders transitioning from physical to digital holdings.
Reporting and Transparency
The final confirmation of these updates has been duly furnished to the relevant stock exchanges, ensuring transparency for all market participants. This process reflects the company’s ongoing commitment to operational efficiency and high standards of corporate governance regarding shareholder records and equity management.
Source: BSE
